Medtronic has selected SurModics' proprietary hydrophilic technology to use on its Resolute Integrity Drug-Eluting Stent (DES) delivery system to treat coronary artery disease (CAD).

SurModics president and CEO Gary Maharaj said they are extremely pleased that their hydrophilic coating was selected for use on the delivery catheter of Medtronic’s Resolute Integrity DES delivery system.

"SurModics values the long-standing relationship with Medtronic and remains steadfast in complementing the deliverability of the Resolute Integrity DES through our advanced hydrophilic coating platforms," Maharaj added.

Medtronic’s Resolute DES system has received the US Food and Drug Administration (FDA) approval.